Trial Profile
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours; Non-small cell lung cancer; Renal cancer
- Focus Pharmacokinetics
- 01 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Aug 2011 New trial record